Cipla Ltd.

NSE: CIPLA | BSE: 500087 | ISIN: INE059A01026 | Industry: Pharmaceuticals
| Mid-range Performer
1485.8000 -5.20 (-0.35%)
NSE Aug 08, 2025 15:31 PM
Volume: 920.3K
 

logo
Cipla Ltd.
13 Aug 2016
1485.80
-0.35%
Motilal Oswal
US impacted by high base; regulatory actions in India; currency volatility in EM: Although US base business (ex Nexium and Invagen) grew >30% YoY, overall US sales declined 26% YoY to USD98m. CIPLA expects the US portfolio to deliver robust growth on the back of its strong launch pipeline (~15 launches expected in rest of FY17) and enhanced focus on R&D.; Domestic formulation sales grew 5% YoY in 1QFY17 (~2% impact due to regulatory issues). According to IMS, secondary sales grew ~13% in 1Q. South Africa business grew 22% YoY in constant currency, but...
Cipla Ltd. has an average target of 1713.00 from 9 brokers.
More from Cipla Ltd.
Recommended